Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (271-280 of 294) with videos related to

Pageof 30
Sort By:
European Urology|August 25, 2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionRoger Li, Patrick J Hensley, Shilpa Gupta, et al.
JCI Insight|September 10, 2024
Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancerKarthik Reddy Kami Reddy, Danthasinghe Waduge Badrajee Piyarathna, Jun Hyoung Park, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 31, 2017
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder CancerFeng Jin, Jose Thaiparambil, Sri Ramya Donepudi, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder CancerDavid J McConkey, Brian C Baumann, Stephanie Cooper Greenberg, et al.
The Journal of Urology|January 5, 2022
Reply by AuthorsSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
The Journal of Urology|December 17, 2021
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final ReportSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2024
Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder CancerFeng Jin, Jose Thaiparambil, Sri Ramya Donepudi, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology|July 8, 2020
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trialNir Kleinmann, Surena F Matin, Phillip M Pierorazio, et al.
European Urology|April 10, 2017
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Hussam Al Deen Ashab, Nicholas Erho, et al.
Pageof 30

Showing results (271-280 of 294) with videos related to

Sort By:
Pageof 30
European Urology|August 25, 2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionRoger Li, Patrick J Hensley, Shilpa Gupta, et al.
JCI Insight|September 10, 2024
Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancerKarthik Reddy Kami Reddy, Danthasinghe Waduge Badrajee Piyarathna, Jun Hyoung Park, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 31, 2017
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder CancerFeng Jin, Jose Thaiparambil, Sri Ramya Donepudi, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder CancerDavid J McConkey, Brian C Baumann, Stephanie Cooper Greenberg, et al.
The Journal of Urology|January 5, 2022
Reply by AuthorsSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
The Journal of Urology|December 17, 2021
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final ReportSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2024
Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder CancerFeng Jin, Jose Thaiparambil, Sri Ramya Donepudi, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology|July 8, 2020
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trialNir Kleinmann, Surena F Matin, Phillip M Pierorazio, et al.
European Urology|April 10, 2017
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Hussam Al Deen Ashab, Nicholas Erho, et al.
Pageof 30